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Abstract
Background: The aim of this study is to develop a methodology to standardize the analysis and reporting of the
patterns of loco-regional failure after IMRT of head and neck cancer.
Material and Methods: Twenty-one patients with evidence of local and/or regional failure following IMRT for
head-and-neck cancer were retrospectively reviewed under approved IRB protocol. Manually delineated recurrent
gross disease (rGTV) on the diagnostic CT documenting recurrence (rCT) was co-registered with the original
planning CT (pCT) using both deformable (DIR) and rigid (RIR) image registration software. Subsequently, mapped
rGTVs were compared relative to original planning target volumes (TVs) and dose using a centroid-based
approaches. Failures were then classified into five types based on combined spatial and dosimetric criteria;
A (central high dose), B (peripheral high dose), C (central elective dose), D (peripheral elective dose), and E
(extraneous dose).
Results: A total of 26 recurrences were identified. Using DIR, recurrences were assigned to more central TVs
compared to RIR as detected using the spatial centroid-based method (p = 0.0002). rGTVs mapped using DIR had
statistically significant higher mean doses when compared to rGTVs mapped rigidly (mean dose 70 vs. 69 Gy, p = 0.
03). According to the proposed classification 22 out of 26 failures were of type A (central high dose) as assessed by
DIR method compared to 18 out of 26 for the RIR because of the tendencey of RIR to assign failures more
peripherally.
Conclusions: RIR tends to assigns failures more peripherally. DIR-based methods showed that the vast majority of
failures originated in the high dose target volumes and received full prescribed doses suggesting biological rather
than technology-related causes of failure. Validated DIR-based registration is recommended for accurate failure
characterization and a novel typology-indicative taxonomy is recommended for failure reporting in the IMRT era.
Keywords: Patterns of failure, IMRT, Head-and-neck cancer, Deformable image registration
Introduction
Intensity-modulated radiation therapy (IMRT) is one of
the most important innovations in modern radiation ther-
apy and represents a paradigm shift in the treatment of
head and neck cancers (HNCs). However, there are certain
hazards that may increase the risk of loco-regional failure
(defined as tumor persistence or recurrence) including in-
adequate definition of the tumor extension and clinically
important target volumes (TVs), uncertainties related to
daily positioning, weight loss or deformation of tumor and
normal tissues during the course of treatment, and uncer-
tainties in plan optimization, dose calculation and treat-
ment delivery [1–5].
The accurate and specific definition of the exact site of
failure, in addition to the radiation dose given to this site
is, therefore, mandatory to identify the possible cause(s)
of failure. The classic definition of failures as “local”, or
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“regional”, was appropriate in the setting of conventional
radiotherapy using large homogeneous dose-volumes,
but is no longer helpful nor descriptive of distinct types
of failure in patients treated with IMRT [6–8].
Several previous efforts have addressed the importance
of studying the patterns of failure after IMRT treatment of
HNCs, [2, 4, 9–13] with most reporting failures as
“infield”, “marginal” or “outfield” based on the percentage
of overlap between the failure volume and the respective
TV on the treatment planning CT (pCT) [4, 9, 10, 12, 13].
The ability to accurately describe the relation of failure
to original TVs and dose mandates a fairly precise
method to co-register the diagnostic CT documenting
recurrence (rCT) to the original pCT. However, the ma-
jority of the previous studies implemented mainly rigid
image registration techniques (RIR) [2, 4, 10, 12, 13].
RIR is simple, quick and widely used but it allows only
for 6° of freedom and doesn’t account for changes in the
shapes or relative positions of different regions-of-
interests (ROIs) [14]. Emerging data demonstrate the
superiority of deformable image registration (DIR) com-
pared to RIR in registering pCT to on-treatment CT or
conebeam CT in the setting of image guided radiother-
apy (IGRT) for HNCs [15–17]. However, very few stud-
ies addressed DIR software implementation for the
purpose of registering the diagnostic rCT to the original
pCT [6, 7].
Our group has recently validated different registration
techniques used for co-registering diagnostic contrast en-
hanced head and neck CT to non-contrast planning CT
and showed DIR was superior for this application [18]. As
a continuation of these efforts and to validate DIR as a
tool to improve accurate definition of the patterns of loco-
regional failure in the era of IMRT for HNCs, we sought
to undergo the following specific aims:
1) Develop a workflow methodology to standardize the
analysis of HNCs patterns of failure using both
geometric and dosimetric parameters.
2) Assess the impact of registration (rigid vs.
deformable) techniques on patterns of failure
quantitative analytic parameters.
3) Develop a granular classification and nomenclature




Tumor registry data for patients diagnosed with head
and neck squamous cell carcinoma, whom were treated
by IMRT at The University of Texas, MD Anderson
Cancer Center between 2006 and 2009, were retrospect-
ively reviewed under an institutional review board ap-
proval. 600 patients were identified, of those 103 had a
documented recurrence. A total of 21 cases were ran-
domly selected from the recurrence dataset based on the
following eligibility criteria: IMRT given for curative in-
tent; treatment of intact tumor (i.e. post-operative cases
were excluded); equal distribution of various head and
neck subsites (i.e. nasopharynx, oropharynx, hypopharynx,
and lateral neck “i.e. neck nodes of unknown primary
site”); radiological evidence of local and/or regional failure;
available CT scan of failure site prior to any salvage ther-
apy; and pathologic and/or radiologic evidence of recur-
rence (i.e. biopsy, or high SUV on PET).
IMRT treatment planning and delivery
All patients had been positioned supine in an individualized
thermoplastic head and shoulder mask for CT simulation
and treatment and a custom dental stent used as an
intraoral immobilization device [19, 20]. A treatment
pCT scan was used for defining TVs. Target volume
definition was done in Pinnacle treatment planning
system (Pinnacle, Phillips Medical Systems, Andover,
MA), with rigorous multi-physician target delineation
and quality assurance [21, 22].
Treatment was uniformly delivered using Varian (Varian
Medical Systems, Palo Alto, CA) linear accelerators
delivering 6-MV photons. Three clinical target volumes
(CTVs) were typically defined. CTV definitions and dose
prescriptions are summarized in Additional file 1:
Table S1. Treatment was delivered in a conventional frac-
tionation scheme (average 33 fractions). Patients were
treated using a monoisocentric technique with an antero-
posterior low-neck supraclavicular field matched to the
IMRT fields or using whole neck IMRT for cases where
gross nodes are located at the match line.
Post-treatment follow up
Initial post-treatment evaluations were made at 8–12
weeks after therapy completion and subsequently every
2–3 months for the first year, every 3–4 months for the
second year, and at least twice a year up to 5 years.
Loco-regional failure
Cases where local and/or regional recurrence was re-
corded had their immediate post-failure diagnostic im-
ages exported as DICOM files from the clinical PACS
system to the treatment planning system, where radio-
logical evident recurrent gross disease (rGTV) was
manually contoured by a radiation oncologist (ASRM)
and reviewed by a head and neck service-specific attend-
ing radiation oncologist (CDF).
Image registration
For each patient, the rCT or rPET-CT was co-registered
with pCT using both rigid and deformable image registra-
tion techniques. DIR was performed using a commercial
Mohamed et al. Radiation Oncology  (2016) 11:95 Page 2 of 10
software (ADMIRE, Elekta AB, 2015) validated previously
by our group for the registration of contrast-enhanced
diagnostic CT to non-contrast enhanced planning CT
[18]. Deformation vector fields were obtained from DIR
algorithm, mapping the deformation of the rCT onto the
pCT. Subsequently, in a custom written Matlab routine
(MATLAB R2013a, The MathWorks Inc., Natick, MA,
2013), pCT; dose grid; original plan TVs; rCT; and rGTVs
were imported. The deformation fields were then applied
to rGTVs segmented on the rCT to convert them into ‘de-
formed rGTVs’ on the pCT.
Evaluation of deformed rGTVs relative to original
planning TVs was done using both centroid-based
method that assumed the center of mass of rGTV was
the origin of the recurrence volume and its location was
compared relative to planning TV after applying deform-
ation vector fields (DVF). Simultaneously, RIR was per-
formed using the rigid co-registration tool available in
the Pinnacle planning system to rigidly align rCT to
pCT, following that rGTVs where exported to patient’s
plan where dose volume histograms (DVHs) and rGTV
centroids were generated and analysis metrics were cal-
culated. Figure 1 illustrates the workflow process of our
registration methodology.
Analysis of failure metrics
For both RIR and DIR mapped rGTVs the following
metrics were evaluated:
1) Recurrence volume, 2) Location of the centroid
relative to planning TV: Centroid is the central voxel of
the recurrence volume plus added 2 mm margin to ac-
count for registration error, 3) Spatial relationship of
rGTV centroids to IMRT/supraclavicular match line and
ipsilateral parotid in case of peri-parotid failure, and 4)
Mean and maximum dose to rGTVs, dose to 95 % fail-
ure volume (fD95%), and mean dose to centroid volume.
Fig. 1 Workflow process of patterns of loco-regional failure registration process
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Classification of failure
In order to refine our reporting and quality assurance
practices using a standard nomenclature, we developed a
granular typology of failure categories relative to the
planning TV and dose. As illustrated in Fig. 2, failures
were classified into five types based on combined spatial
and dosimetric criteria:
 Type A: Central high dose failure, where the mapped
failure centroid originates in high dose TV and the
dose to 95 % failure volume (fD95%) is ≥95 % dose
prescribed to corresponding TV of origin.
 Type B: Peripheral high dose failure, where the
mapped failure centroid originates from high dose
TV but its fD95% receives <95 % dose prescribed to
this TV.
 Type C: Central elective dose failure, where the
failure centroid originates from elective dose TV
and its fD95% receives ≥95 % dose prescribed to the
respective TV.
 Type D: Peripheral elective dose failure, where the
failure centroid originates from elective dose TV and
its fD95% receives <95 % dose prescribed to the
respective TV.
 Type E: Extraneous dose failure, where the failure
centroid originates outside all TVs.
For patients treated with low-neck supraclavicular field
matched to the IMRT fields, two additional types were
added:
 Type F: Junctional failures at the site of IMRT/
supraclavicular match line.
 Type G: Low neck failures at the site of low-neck
supraclavicular field.
Statistical analysis
Non parametric statistics were used to compare analysis
metrics for centroid locations and dosimetric parameters
of failures mapped using RIR versus DIR registration
Fig. 2 Classification scheme of IMRT patterns of failure using combined centroid based geometric method coupled with the dosimetric
parameters. Panel a) shows an example of types A (central high dose) and C (central elective dose) failures, panel b) shows an example of types
B (peripheral high dose) and D (peripheral elective dose) failures, and panel c) shows an example of type E (extraneous dose) failure.
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techniques. A p-value ≤ 0.05 was deemed significant.
Statistical assessment and data tabulation was performed
using JMP v 11Pro (SAS institute, Cary, NC).
Results
Patients
A total of 21 patients with HNSCC were included in this
pilot methodology/workflow development study. Median
age was 58 years (range 30–75), and 86 % were men.
Patient, disease, and treatment characteristics are pre-
sented in Table 1. Recurrences were delineated using
diagnostic contrast-enhanced CT in 16 patients and
using PET-CT in 5 patients.
Spatial/dosimetric failure mapping
Spatial mapping
A total number of 26 rGTVs were delineated. Mean
rGTVs volume was 12.5 cm3 (range 1–105). The regis-
tration method independently affected the spatial loca-
tion of mapped failures. Failures mapped using DIR
were significantly assigned to more central TVs com-
pared to failures mapped using RIR. 38 % of centroids
(n = 10) mapped using RIR were located peripheral to
the same centroids mapped using DIR (p = 0.0002).
Table 2 illustrates the sites and geometric details of all
failures mapped to the pCT.
Dosimetric mapping
rGTVs mapped using DIR had statistically significant
higher mean doses when compared to rGTVs mapped
rigidly (mean dose 70 vs. 69 Gy, p = 0.03) while compari-
son of mean fD95% was not statistically significant
(mean fD95% 68 vs. 66 Gy, p = 0.07), and comparison of
maximum, and centroid doses showed no-significant dif-
ferences between both registration methods (p = 0.7 and
0.4, respectively). Additional file 1: Table S2 shows the
dosimetric details of all failures.
Classification of failure
Based on the proposed classification of failure using
both the spatial location of the centroids of the mapped
failure volumes coupled with the dosimetric parameters
(as illustrated in Fig. 2), 22 (84.6 %) out of the 26 failures
mapped using DIR were of type A, one of type B, 2 of
type C, and one of type G. Whereas, 18 (69 %) out of
the 26 failure mapped using RIR were of type A, 5 of
type B, 2 of type C and one of type G. Figure 3 illustrates
the difference in classification using both registration
methods. There was no type F (junctional) failures in pa-
tient subset treated using anteroposterior low-neck
supraclavicular field matched to the IMRT fields. Addition-
ally, no peri-parotid failures were detected.
This combined spatial/dosimetric analysis shows that
while 10 centroids (38 %) of RIR mapped rGTVs were
located peripheral to the same centroids mapped using
DIR as shown in Table 2. However, after adding the
dosimetric component of analysis, only 4 of those 10
RIR mapped rGTVs were peripheral high dose failures
(type B) and the other 6 were central high dose failure
(type A) because despite the centroids were spatially per-
ipheral in location to the respective DIR ones but dosi-
metrically, the rGTVs 95 % volumes still had ≥95 %
dose. Figure 4 shows an example of the differences in
Table 1 Patient demographics, disease, and treatment
characteristics
Total



























Radiation alone 4 (19)
Concurrent ChemoRadiation 9 (43)
Induction Chemotherapy + Radiation 1 (5)
Induction Chemotherapy + Concurrent ChemoRadiation 7 (33)
Radiation dose
Mean (SD) 69.2 (1.7)
Radiation fractions
Mean (SD) 33 (2)
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spatial and dosimetric parameters for a DIR versus RIR
mapped failure. Those 4 rGTVs were seen in the follow-
ing patients: two nasopharyngeal (one primary “Fig. 4”
and one nodal site); one oropharyngeal (primary site);
and one unkown primary (nodal site). The secondary
qualitative review by expert radiation oncologists (CDF,
DIR) of those 4 patients agreed with DIR classification
that those recurrences are actually central rather than
peripheral in origin.
Discussion
Traditionally, failure reporting for HNCs has simply
classified disease as “local”, “regional”, or “locoregional”,
thus relating location of failure to a crude anatomic
reference. However, such a reporting language gives no
information regarding radiation fields/volumes, or deliv-
ered dose. In the pre-IMRT era, when large fields of
homogenous dose were used, the definition of “in-field”
failure (i.e. within the field borders) or “marginal” failure
(i.e. adjacent to the block edges) were intuitive descrip-
tors relating treatment parameters to sites of failure.
However, in the current era of conformal therapy [23, 24],
dose gradients, and multiple TVs make relating spatially
accurate information about dose and recurrence far more
complicated for IMRT plans. In the same way that a stan-
dardized method for analysis and reporting for TVs has
been undertaken successfully [23–25], a similar effort is
desirable for pattern of failure reporting. In our opinion,
reporting failure using only anatomic/field referents is in-
sufficient for complex multi-volume/multi-dose plans,
and obscures clinically useful information which might
lead to improvements in future studies.
Likewise, the requirement of rigorous assurance for
correctly localizing disease after-therapy is increased in
terms of required spatial accuracy. The steep dose gradi-
ents of modern IMRT plans and proximate transition
from high-risk CTVs to intermediate- or lower-risk
CTVs implies inaccurate registration will erroneously as-
sign the location of failure to incorrect dose/prescription
volume. We, in fact, show RIR for IMRT plans resulted
in incorrect localization relative to prior TVs and dose
in 16 % of failures in the current pilot dataset. Conse-
quently, this study presents a methodology and workflow
that involves the application of quality assured DIR soft-
ware as a tool to standardize co-registration and to cor-
rectly attribute sites of loco-regional failure.
Almost all previous studies have used RIR to de-
scribe the patterns of loco-regional failure after IMRT
[2, 10, 12, 13]. Chao et al. [10] reported 17/126 loco-
regional failures treated by definitive or postoperative
IMRT; 53 % of failures were inside CTV1, 12 % mar-
ginal to CTV1, 6 % marginal to CTV2, and 28 %
Table 2 Geometric details of failed rGTVs
n. Percent
N. of recurrences 26
Recurrence volume
Mean (SD) 12.5 (23)






Supraclavicular field 1 (4)





Supraclavicular field 1 (4)
Abbreviations: DIR Deformable image registration, RR Rigid Registration, GTV
gross tumor volume, CTV clinical target volume, PTV planning target volume
Fig. 3 Bar chart illustrating the difference in failure classification using rigid (RIR) vs. deformable (DIR) image registration methods
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were out of field. Eisbruch et al. [2] reported on 21
recurrences in 133 patients with non-nasopharyngeal
HNCs treated with parotid-sparing IMRT; 17/21 were
in-field. Daly et al. [12] reported on 69 HNCs treated
with parotid-sparing IMRT; 8 patients developed a
loco-regional failure, 7 relapsed within the high-dose
CTV, with one junctional failure observed. Sanguineti
et al. [13] described the patterns of failure for 50 pa-
tients with IMRT for oropharyngeal SCC; 5 recur-
rences were related to high dose regions while 4 were
at the low dose regions. All these reports relied on
RIR, known to be less spatially accurate than DIR
[18]; it is conceivable these results might be altered if
DIR methods were used. Due et al. [7] reported that
DIR showed slightly better reproducibility in identifi-
cation of the site of recurrence origin compared to
RIR. Our previous work [18], as well as the current
study, confirm the qualitative superiority, in HNC ap-
plications, of DIR for CT-CT registration.
In our classification scheme, we designed a combined
geometric/dosimetric typology definition to avoid the
drawbacks of using each method separately. Centroid
only method suppose a single point of origin and ignore
the dose given to the whole area of recurrence while the
dosimetric only analysis is agnostic to the geometric re-
currence origin. Due et al. [7] previously reported that
focal methods, such as the centroid method we used, are
more accurate to localize the origins of loco-regional re-
currences than volume overlap methods, which may in-
correctly assign recurrences to more peripheral TVs.
Raktoe et al. [8] further confirmed the superiority of
focal methods like centroid expansion to the volumetric
Fig. 4 A case of T2N0 Nasopharyngeal carcinoma recurred 63 months after IMRT. The upper panel shows the axial, coronal and sagittal images of
a RIR mapped rGTV on the original pCT where its centroid is located at CTV1and the 95 % rGTV volume contained on more peripheral PTV2
(contour not shown). The middle panel shows DIR mapped rGTV on the original pCT where its centroid located at GTV and the 95 % rGTV
volume contained on more peripheral CTV2. The lower panel shows RIR and DIR mapped rGTVs overlaid to plan isodose line. Note that RIR rGTV
fD95% extends beyond the 95 % isodose line “66.5 Gy” (red arrow in sagittal image) which would erroneously characterize it as type B failure,
while in fact DIR shows it as a type A failure (i.e. the fD95% of DIR mapped rGTV is completely encapsulated with 95 % isodose line, shown by
white arrow in sagittal image)
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method in identifying the origin of loco-regional recur-
rences. The combined method we used identify the esti-
mated site of recurrence origin relative to the respective
TV in the planning CT and then compare the dose to
the mapped recurrence volume with the dose prescribed
to the TV of origin. Using this method, our results
showed that DIR significantly assigned failures to more
central TVs and doses compared to RIR concordant with
the results of Due et al. [7].
Our proposed nomenclature allows granular reporting
of different types of failure. In our classification, type A
“central high dose” failures, are considered to be bio-
logical failures, as they likely represent resistance to
maximal therapy, and thus could not conceivably be pre-
vented by technical/operator dependant processes in-
cluding IMRT QA or delineation alteration. Type A
failures motivate future investigation of alternative treat-
ment stratgies (e.g. integration of novel targeted drug
therapies or dose escalation to identifiable biologically
aggressive subvolumes). Likewise, type E “extraneous
dose” failures cannot be modified by IMRT QA pro-
cesses. They represent a possible diagnostic or decision
error rather than a target delineation error (i.e. “One will
never hit what one does not aim at.”). However, type B,
C, and D failures are of a special concern since they
entail potential technical or radiotherapy process fail-
ures. Type C “central elective (intermediate or low)
dose” failures may be prevented by prescribing higher
doses (i.e. shifting to higher CTV levels). Importantly,
type B “peripheral high dose” or D “peripheral elective
dose” failures necessitate a rigorous QA process includ-
ing triple DIR registration of pre-therapy diagnostic im-
aging (diagnostic CT, MRI, and/or PET-CT) to pCT and
the earliest rCT, to assess the potential causes: potential
target delineation or dose delivery error (modifiable) ver-
sus overgrown recurrence that represents actual type A
or C failure which is converted to type B or D, respect-
ively, due to rapidly progressive disease or neglected late
diagnosed recurrence (not modifiable). This involves
multi-physician review of planning and recurrence
contours, and review of IGRT data (i.e. set-up error,
adaptive replanning datasets), as well as examination of
the follow-up interval between surveillance images. By
cataloging type B/D errors, we can then address the rele-
vant issues dynamically for future patients. For instance,
the only type B patient (i.e. using DIR methodology),
was noted on secondary review of diagnostic imaging to
have subsequent intracranial extension, route of failure,
despite optimum delineation and dose coverage.
The secondary qualitative review by expert radiation on-
cologists (CDF, DIR) of all the clinical and imaging data of
the four additional recurrences that were classified as per-
ipheral high dose (type B) using RIR while were type A
using DIR, concurred with DIR classification that
those recurrences are actually central rather than per-
ipheral in origin.
In this limited pilot dataset, our results showed the
majority (84.6 %) of DIR mapped failures were of type A
indicating, that biological, non-technically/non-operator
dependant explanations for failure predominated. How-
ever, using RIR type A failures would have been errone-
ously reported as comprising only 69 %. These results
assert the need for a robust, quality assured image regis-
tration technique, as error in the registration process
would invalidate subsequent results and thus might
deceptively indicate a greater rate of technical/operator-
attributable therapy failures than DIR demonstrates. The
current study, while underpowered to make clinical ex-
trapolations due to limited number of patients, nonethe-
less serves as a benchmark to describe our standardized
analytic and reporting method. Already, RTOG 1216, for
example, contains provisions regarding collection of im-
aging data post-failure [26], which will allow careful ana-
lysis, and process quality improvement for future trials
and large scale datasets.
Conclusions
Rigid image registration method tends to assigns failures
more peripherally compared with deformable method.
Using DIR, the vast majority of failures in the presented
pilot study originated in the high dose target volumes
and received full prescribed doses suggesting biological
rather than technology-related causes of failure. We
heavily recommend a validated DIR-based registration
technique in addition to granular combined geometric-
and dosimetric-based failure characterization using
novel typology-indicative taxonomy as a standard part of
large-scale patterns of failure reporting in the IMRT era.
Additional file
Additional file 1: Table S1. IMRT target volume definitions and dose
prescription. Table S2. Dosimetric patterns of failure. (DOCX 16 kb)
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